NCT00112671View on ClinicalTrials.gov

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and UreterRegional Transitional Cell Cancer of the Renal Pelvis and UreterStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder
Interventions
DRUG

sorafenib tosylate

Given orally 400mg orally twice daily

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital Phase 2 Consortium, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00112671 - Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract | Biotech Hunter | Biotech Hunter